Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany

Related Experiment Video

Updated: May 23, 2026

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity

Published on: May 12, 2020

Anke Stroet, Claudia Hemmelmann, Michaela Starck

Therapeutic Advances in Neurological Disorders

|March 22, 2012

Abstract

Background:

The incidence of therapy-related acute leukaemia (TRAL) in mitoxantrone treatment in multiple sclerosis (MS) is controversially discussed.

Methods And Results:

In a retrospective meta-analysis from six centres, we observed six cases of acute myeloid leukaemia (AML) (incidence 0.41% for patients with mean follow up after end of treatment of 3.6 years, n = 1.156; incidence 0.25% for all patients, n = 2.261). Potential influencing factors such as myelotoxic or glucocorticosteroid pretreatment/cotreatment were present in all but one case of TRAL. Between 1990 and 2010, 11 cases of TRAL were reported to the Drug Commission of the German Medical Association (estimated risk of 0.09-0.13%).

Conclusions:

Regional differences in reported TRAL incidence may point to confounding cofactors such as administration protocols and cotreatments.

Keywords:

escalation therapy leukaemia mitoxantrone multiple sclerosis risk profile

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Articles linked to this work by shared authors, journal, and citation graph.

Calibrating Machine Learning Approaches for Probability Estimation Without Calibration Data.

Statistics in medicine·2026

Consensus on the Use of Intrathecal Gene Therapy for Spinal Muscular Atrophy.

Neuropediatrics·2026

Associations of CMR-based pulse wave velocity and aortic distensibility with infrarenal ultrasound-based aortic parameters in the Hamburg City Health Study.

Clinical research in cardiology : official journal of the German Cardiac Society·2026

Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland - part II - expert based recommendations for surveillance and management of side-effects.

Journal of neuromuscular diseases·2026

Interpretation of Pharmacometabolomics Results: Fingerprint of Drug Exposure or Confounder Effects? Insights from a Urinary Metabolomics Study with Voriconazole in Healthy Participants.

International journal of molecular sciences·2026

The phenotypic spectrum and genetic determinants of severe spinal muscular atrophy in individuals with a single SMN2 copy: an international retrospective observational study.

EClinicalMedicine·2026

See all related articles